JP2024170456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024170456A5 JP2024170456A5 JP2024144789A JP2024144789A JP2024170456A5 JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5 JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203183.1 | 2018-10-29 | ||
| EP18203183 | 2018-10-29 | ||
| US201862752641P | 2018-10-30 | 2018-10-30 | |
| US62/752,641 | 2018-10-30 | ||
| PCT/US2019/058648 WO2020092427A1 (en) | 2018-10-29 | 2019-10-29 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
| JP2021524345A JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Division JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024170456A JP2024170456A (ja) | 2024-12-10 |
| JP2024170456A5 true JP2024170456A5 (enExample) | 2025-07-07 |
Family
ID=70462698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210332131A1 (enExample) |
| EP (1) | EP3873942A4 (enExample) |
| JP (2) | JP2022506761A (enExample) |
| KR (1) | KR20210096612A (enExample) |
| CN (1) | CN113260632A (enExample) |
| AU (1) | AU2019369397A1 (enExample) |
| CA (1) | CA3118312A1 (enExample) |
| GB (1) | GB2596411B (enExample) |
| WO (1) | WO2020092427A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202110626SA (en) * | 2019-03-27 | 2021-10-28 | Umc Utrecht Holding Bv | Engineered iga antibodies and methods of use |
| EP4232052A4 (en) * | 2020-10-22 | 2025-08-20 | Actinium Pharmaceuticals Inc | COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER |
| CN116829698A (zh) * | 2020-12-07 | 2023-09-29 | 加利福尼亚大学董事会 | 通过SIRP-α衔接体的先天免疫细胞沉默 |
| US20250197502A1 (en) * | 2022-02-09 | 2025-06-19 | Exelixis, Inc. | Multispecific binding agents and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226878D0 (en) * | 2002-11-18 | 2002-12-24 | Univ Warwick | Antibodies |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| CA2771336C (en) * | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| WO2013087911A1 (en) * | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| RU2693078C2 (ru) * | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
| KR20150130349A (ko) * | 2013-03-15 | 2015-11-23 | 메르크 파텐트 게엠베하 | 4가 이중특이적 항체 |
| ES2923641T3 (es) * | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
| US10087257B2 (en) * | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| WO2016024021A1 (en) * | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| CN108290948B (zh) * | 2015-09-21 | 2021-10-29 | 伊拉兹马斯大学医疗中心 | 抗-cd47抗体及使用方法 |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| PL3507303T3 (pl) * | 2016-09-01 | 2025-12-08 | Tigatx, Inc. | Przeciwciała CD20 |
| JP7117311B2 (ja) * | 2017-01-26 | 2022-08-12 | ゼットリップ ホールディング リミテッド | Ｃｄ４７抗原結合単位およびその使用 |
| PL3658141T3 (pl) * | 2017-07-24 | 2023-06-12 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
| CN111032692A (zh) * | 2017-08-08 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗 |
-
2019
- 2019-10-29 KR KR1020217016137A patent/KR20210096612A/ko active Pending
- 2019-10-29 CN CN201980087109.4A patent/CN113260632A/zh active Pending
- 2019-10-29 WO PCT/US2019/058648 patent/WO2020092427A1/en not_active Ceased
- 2019-10-29 JP JP2021524345A patent/JP2022506761A/ja active Pending
- 2019-10-29 AU AU2019369397A patent/AU2019369397A1/en active Pending
- 2019-10-29 CA CA3118312A patent/CA3118312A1/en active Pending
- 2019-10-29 EP EP19879444.8A patent/EP3873942A4/en active Pending
- 2019-10-29 GB GB2107478.6A patent/GB2596411B/en active Active
-
2021
- 2021-04-28 US US17/242,793 patent/US20210332131A1/en active Pending
-
2024
- 2024-08-26 JP JP2024144789A patent/JP2024170456A/ja active Pending